Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Physical Activity Promotes Health and Reduces Cardiovascular Mortality in Depressed Populations: A Literature Overview.International journal of environmental research and public health · 2020Pooled it
- Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial.Scientific reports · 2022Trial
- Interferon-beta-induced changes in neuroimaging phenotypes of appetitive motivation and reactivity to emotional salience.NeuroImage. Clinical · 2019Trial
- The interaction between the immune system and the autonomic nervous system in the pathophysiology of major depressive disorder: a scoping review.Brain, behavior, & immunity - health · 2026Review
- A Novel Integrative Framework for Depression: Combining Network Pharmacology, Artificial Intelligence, and Multi-Omics with a Focus on the Microbiota-Gut-Brain Axis.Current issues in molecular biology · 2025Review
- The psychobiotic revolution: comprehending the optimistic role of gut microbiota on gut-brain axis during neurological and Gastrointestinal (GI) disorders.World journal of microbiology & biotechnology · 2025Review
- Review
- Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway.Molecular psychiatry · 2021Article
- Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review.International journal of molecular sciences · 2020Review
- Gut microbial metabolites in depression: understanding the biochemical mechanisms.Microbial cell (Graz, Austria) · 2019Review
- A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety.BMC gastroenterology · 2019Article
- The effects of roux en y gastric bypass surgery on neurobehavioral symptom domains associated with severe obesity.Physiology & behavior · 2019Article
- Finding the needle in the haystack: systematic identification of psychobiotics.British journal of pharmacology · 2018Review
- Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.The Journal of nutritional biochemistry · 2018Review
- Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.International journal of molecular sciences · 2018Review
- Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals.Trends in neurosciences · 2016Review
- Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals.Journal of psychiatry & neuroscience : JPN · 2016Article
- Role of neuro-immunological factors in the pathophysiology of mood disorders.Psychopharmacology · 2016Review
- Hepatitis C virus and neurological damage.World journal of hepatology · 2016Review
- The Gut-Brain Axis: The Missing Link in Depression.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
In patients at high risk for recurrence of malignant melanoma, interferon-α (IFN-α), a stimulator of innate immunity, appears to induce distinct neurobehavioral symptom dimensions: a mood and anxiety syndrome, and a neurovegetative syndrome, of which the former is responsive to prophylactic administration of paroxetine. We sought to determine whether symptom dimensions (and treatment responsiveness) arise in patients with hepatitis C administered IFN-α and ribavirin. In a randomized, double-blind, 6-month study, 61 patients with hepatitis C eligible for therapy with IFN-α and ribavirin received the antidepressant paroxetine (n=28) or a placebo (n=33). Study medication began 2 weeks before IFN-α/ribavirin therapy. Neuropsychiatric assessments included the 10-item Montgomery-Asberg Depression Rating Scale (MADRS). The items of the MADRS were grouped into depression, anxiety, cognitive dysfunction, and neurovegetative symptom dimensions, and analyzed using a mixed model. By 2 weeks of IFN-α/ribavirin therapy, all four dimensions increased, with the symptom dimensions of anxiety and cognitive dysfunction fluctuating and worsening, respectively, in both groups over time. The depression symptom dimension was significantly lower in the paroxetine treatment group (p=0.04); severity of the neurovegetative symptom dimension was similar in both groups. Similar to patients with malignant melanoma receiving high-dose IFN-α, the depression symptom dimension is more responsive to paroxetine treatment in individuals undergoing concomitant IFN-α/ribavirin therapy. However, the anxiety, cognitive dysfunction, and neurovegetative symptom dimensions appear less responsive to prophylactic paroxetine administration. Different neurobiologic pathways may contribute to the responsiveness of IFN-α-induced symptom dimensions to antidepressant treatment, requiring relevant psychopharmacologic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.